Last reviewed · How we verify
NCT04401085: SARSCoV2CZPrev
COVID-19: Herd Immunity Study in the Czech Republic
trial testing SARS-CoV-2 diagnostic rapid test in COVID in 27,000 participants. Completed in 1 May 2020.
1 May 2020
Quick facts
| Lead sponsor | Institute of Health Information and Statistics of the Czech Republic |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 27,000 |
| Start date | 23 April 2020 |
| Primary completion | 1 May 2020 |
| Estimated completion | 1 May 2020 |
| Sites | 1 location across Czechia |
Drugs / interventions tested
- SARS-CoV-2 diagnostic rapid test
- Quantitative analysis of SARS-CoV-2 antibodies
Conditions studied
- COVID — all drugs for COVID →
- SARS-CoV 2 — all drugs for SARS-CoV 2 →
Sponsor
Institute of Health Information and Statistics of the Czech Republic
Who can join
Adults 8 to 89, any sex, with COVID or SARS-CoV 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the SARS-CoV-2-CZ-Preval study is to quantify the prevalence of individuals with a history of SARS-CoV-2 coronavirus infection in the Czech population, except for those diagnosed with COVID-19 by methods based on direct detection of SARS-CoV- 2, including individuals with a subclinical course of the disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04401085
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SARS-CoV-2 diagnostic rapid test
Trials testing the same drug.
- NCT04453280 — Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity) · completed
Other recruiting trials for COVID
Currently open trials in the same condition.
- NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
- NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
- NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting
Other Institute of Health Information and Statistics of the Czech Republic trials
Trials by the same sponsor.
- NCT07371000 — Early Detection of OAB and Elimination of Negative Impact on Quality of Life · NA · recruiting
- NCT07015203 — The Combined First Trimester Screening · recruiting
- NCT06865326 — Early Detection of CTEPH in Patients After APE · recruiting
- NCT07057453 — National Childhood Obesity Prevention Programme BE FIT 24 · NA · recruiting
- NCT06499623 — Early Detection of Malnutrition in Oncology Patients and Elderly Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04401085 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Health Information and Statistics of the Czech Republic
- Last refreshed: 1 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04401085.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing